Summary
Joanne M. Donovan, the Chief Medical Officer of Edgewise Therapeutics (NASDAQ:EWTX), executed two stock sales on March 27, 2026, disposing of a total of 16,358 shares for approximately $506,734. The sale prices in those transactions ranged from $30.49 to $31.68. Following the transactions, Donovan is recorded as directly owning 9,597 shares of the company.
Transaction details
The insider sales were completed in two separate tranches on March 27, 2026. Aggregate proceeds from the combined disposals are reported at about $506,734, derived from prices spanning $30.49 to $31.68 per share. Records indicate that, after these sales, Donovan retained a direct holding of 9,597 shares of Edgewise Therapeutics common stock.
Market context
The timing of the insider sale coincides with a period of strength for the company’s equity: EWTX shares are trading near their 52-week high and have delivered an 87% return over the previous six months. Independent valuation commentary from InvestingPro, however, characterizes the stock as appearing overvalued relative to its Fair Value estimate. For investors seeking deeper valuation and growth analysis, InvestingPro’s Pro Research Report covering this equity and more than 1,400 other U.S. stocks is cited as an available resource.
Clinical and analyst developments
Edgewise has recently been the subject of several analyst updates alongside clinical disclosures. The company presented long-term findings from the MESA open-label extension trial showing functional stability in participants with Becker muscular dystrophy treated with sevasemten over a period of 3.5 years. That dataset was presented at the 2026 MDA Clinical and Scientific Conference and is highlighted as evidence of the drug’s potential to help maintain patient stability.
Analyst reactions to the company’s data and pipeline prospects have been largely positive. Raymond James reiterated a Strong Buy rating with a $46 price target, and Truist Securities maintained a Buy rating at the same $46 target. JPMorgan elevated its price target to $45, specifically citing expected catalysts in Edgewise’s pipeline, including interest around EDG-7500, an oral cardiac sarcomere modulator. Evercore ISI also raised its target to $45 and noted the significance of EDG-7500’s upcoming 12-week hypertrophic cardiomyopathy (HCM) data expected in 2026. These updates are presented as evidence of analyst confidence tied to recent trial results and forthcoming pipeline milestones.
Takeaway
The insider sale by the company’s CMO is a discrete, quantifiable event: 16,358 shares sold on March 27, 2026, for roughly $506,734, with Donovan retaining 9,597 shares. That transaction occurs against a backdrop of strong recent share performance and upbeat analyst commentary following positive long-term clinical data for sevasemten and attention on upcoming EDG-7500 results. At the same time, third-party valuation commentary cited in reporting flags the stock as trading above its Fair Value estimate.